teer-ZEP-ah-tide
A dual-action weight loss medication that mimics two gut hormones at once for enhanced metabolic results.
Also known as: Mounjaro, Zepbound
FDA approved for: Chronic weight management (Zepbound) · Type 2 diabetes (Mounjaro)
Last reviewed: April 2026
Tirzepatide activates two hormone receptors simultaneously — GLP-1 and GIP. Think of it as semaglutide's more powerful cousin. By hitting two targets instead of one, it produces stronger appetite suppression and better blood sugar control. Clinical trials showed average weight loss of 20–25% of body weight.
Once-weekly injection into belly, thigh, or upper arm
Frequency
Once weekly
Pain Level
●○○ Minimal
Self-Administered
Yes — at home
Typical Range
2.5mg – 15mg
Week 1–4
Starting dose is low. Mild appetite changes, possible nausea.
Month 2–3
Dose titrates up. Noticeable appetite reduction and early weight loss.
Month 6
Typically 15–20% body weight loss. Significant metabolic improvements.
Month 12+
Up to 20–25% weight loss in clinical trials. Full cardiovascular benefits.
Overall: Mild
Nausea
Most common in first weeks, improves with dose titration.
Decreased appetite
Intended therapeutic effect.
Diarrhea
Usually temporary during dose increases.
Injection site reactions
Redness or itching at injection site.
Severe abdominal pain
Could indicate pancreatitis — seek immediate care.
Call your doctor if you experience this.
• Personal or family history of medullary thyroid cancer
• MEN 2 syndrome
• Pregnant or planning pregnancy
• History of pancreatitis
• Insulin — dose adjustment needed
• Sulfonylureas — increased hypoglycemia risk
• Oral contraceptives — may reduce absorption
Pregnancy: Do not use during pregnancy. Stop at least 2 months before planning conception.
Tirzepatide hits two receptors (GLP-1 + GIP) vs semaglutide's one (GLP-1 only). Trials show 5–7% more weight loss with tirzepatide.
Semaglutide
A medication that reduces appetite and helps your body lose weight by mimicking a natural gut hormone.
Liraglutide
An earlier GLP-1 weight loss injection — taken daily instead of weekly, with a strong safety track record.
Retatrutide
A triple-action weight loss molecule targeting three gut hormone receptors at once — the next evolution beyond tirzepatide.
This peptide is available through our protocols.
FDA-approved for at least one indication. Your provider will determine if this is appropriate for you.